Topics

Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT

2016-08-22 11:37:12 | BioPortfolio

Summary

DESIGN:

Disease registry - non-interventional.

INDICATION: Patients failing first or subsequent line treatment for adenovirus and / or cytomegalovirus reactivation post allogeneic hematopoietic stem cell transplantation.

Description

In this disease registry, data on approximately 120 allo HSCT patients who have received salvage treatment (second or later line) with any antiviral therapy for ADV and / or CMV post allogeneic HSCT will be documented; of these 120, at least 40 patients will have been treated with Cell Medica's immune reconstitution ACT as salvage therapy. The patients will be consented prospectively or retrospectively for collection of data. Data will be collected at baseline, 6 months and 1 year after commencement of salvage treatment. Retrospective data collection (for patients who underwent HSCT in 2010 or later) is permitted.

Study Design

Observational Model: Cohort

Conditions

Infectious Complications Following HSCT

Intervention

antiviral therapies for CMV and/or ADV

Location

Birmigham Children Hospital
Birmingham
United Kingdom

Status

Recruiting

Source

Cell Medica Ltd

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-08-22T11:37:12-0400

Clinical Trials [800 Associated Clinical Trials listed on BioPortfolio]

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly cau...

Preemptive Adoptive CMV-CTL Infusion to Prevent Refractory CMV Infection Post Haplo-HSCT

Cytomegalovirus (CMV) infections remain an important cause of morbidity and mortality in allogeneic hematopoietic cell transplant (HSCT) recipients, especially in patients received haploid...

Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly cau...

Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies

For micro residual disease (MRD) positive patients who have undergone at least 2 cycles chemotherapies for their CD19+ B-cell malignancies, there would be much more risks for them to recei...

Safety of Human Lactoferrin hLF1-11 for the Treatment of Infectious Complications Among Haematopoietic Stem Cell Transplant Recipients

The safety and tolerability of hLF 1-11 given in multiple doses has to be established first in HSCT recipients who are at risk of developing, but have not yet developed, infectious complic...

PubMed Articles [6871 Associated PubMed Articles listed on BioPortfolio]

Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States.

While the initial hospitalization accounts for 75% of total healthcare costs during the first 100 days following hematopoietic stem cell transplantation (HSCT), there is a lack of studies evaluating ...

A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir- based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?

With the appearance of direct-acting antiviral agents (DAAs), sofosbuvir (SOF)-based DAAs are recommended for patients with hepatitis C virus (HCV) recurrence after liver transplantation (LT). Whether...

Current practice in vitamin D management in Allogeneic Haematopoietic Stem Cell Transplantation: a survey by the Transplant Complications Working Party of the EBMT.

Beyond its impact on bone health, numerous studies have investigated the immune-regulatory properties of vitamin D, and shown how its deficiency can impact outcomes in allogeneic haematopoietic stem c...

Hematopoietic Stem Cell Transplantation: A Neonatal Perspective.

Allogeneic hematopoietic stem cell transplantation (HSCT) is indicated in various nonmalignant disorders that arise from genetic, hematopoietic, and immune system defects. Many of the disorders descri...

Hepatitis C Virus Treatment with Directly Acting Agents Reduces the Risk of Incident Diabetes - Results from ERCHIVES.

Effect of interferon-based therapies for HCV upon risk of diabetes is controversial. Effect of newer directly acting antiviral agents (DAA) upon this risk is unknown. We sought to determine the effect...

Medical and Biotech [MESH] Definitions

Therapies using arts or directed at the senses.

The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION.

Complications that affect patients during surgery. They may or may not be associated with the disease for which the surgery is done, or within the same surgical procedure.

An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.

An oleanolic acid from GLYCYRRHIZA that has some antiallergic, antibacterial, and antiviral properties. It is used topically for allergic or infectious skin inflammation and orally for its aldosterone effects in electrolyte regulation.

More From BioPortfolio on "Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT"

Quick Search

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...


Searches Linking to this Trial